Imiglucerase Brand Name– Cerezyme
What is Imiglucerase
Imiglucerase is parenteral enzyme used in the treatment of patients with Gaucher’s disease.
Imiglucerase replaces the endogenous enzyme beta-glucocerebrosidase.
Imiglucerase is produced by recombinant DNA technology using Chinese hamster ovary cell cultures and differs from the endogenous enzyme by one amino acid at position 495 where histidine is substituted for arginine.
Imiglucerase was approved by the FDA in March 1994. A related product, alglucerase (Ceredase®), produced from pooled human placental tissue from selected donors, was approved April 1991.
Indications
- Gaucher disease
For enzyme replacement therapy in patients with confirmed Gaucher disease type 1 (GD1) who have at least one of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly
Side Effects
- abdominal pain
- anaphylactoid reactions
- angioedema
- antibody formation
- chest pain (unspecified)
- chills
- cough
- cyanosis
- diarrhea
- dizziness
- dyspnea
- fatigue
- fever
- flushing
- headache
- hypotension
- injection site reaction
- nausea
- peripheral edema
- pruritus
- rash
- sinus tachycardia
- urticaria
- vomiting
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- gelatin hypersensitivity
- pregnancy
- pulmonary hypertension
Interactions
- Miglustat
Miglustat: (Major) Combination therapy with miglustat and imiglucerase is not indicated for Gaucher disease. Miglustat may increase the clearance of imiglucerase, although the clinical significance of this interaction is not yet known.
